NAD+, without the needle.
Compounded NAD+ nasal spray for patients seeking a no-needle route with absorption and use questions addressed honestly.
About 10 minutes. No charge unless your clinician approves.
The coenzyme is familiar. The route is the product decision.
NAD+ is a coenzyme present throughout human cells and involved in the chemistry of energy metabolism and cellular repair systems. That biology is the same reason people become interested in both injectable and nasal NAD+.
The route is the point.
The compounded nasal spray is delivered across the nasal lining rather than by subcutaneous injection. For someone who is interested in NAD+ but knows that needles will make the routine harder to sustain, that practical difference can be meaningful.
The route does not establish equivalence. A nasal spray and an injection are different formulations and delivery routes. The spray avoids the needle and delivers NAD+ intranasally, but evidence has not established that it reproduces injectable exposure or outcomes.
The spray provides a no-needle NAD+ route with clinician-set use and follow-up. Absorption and format differences remain part of the prescribing decision.
Read the evidence →For people interested in NAD+ who know they do not want the syringe.
The Needle-Averse
The biology interests you, but an injection routine does not. You want to know whether a nasal prescription is a medically reasonable way to explore the molecule without building needles into the day.
The Mechanism Reader
Cellular-energy and NAD+-dependent enzyme biology are what caught your attention. You want those mechanisms discussed seriously without promises about how the spray will make you feel.
The Routine Minimalist
You know a treatment only fits if the routine fits too. A nasal spray is a simpler practical ask, provided your clinician determines the formulation belongs in the plan.
Compounded NAD+ nasal spray is not an FDA-approved drug product. A licensed provider sets candidacy and cadence from your full intake, and results vary.
This might not be the right fit if:
- Active nasal or sinus infection, recent nasal surgery, or significant nasal polyps
- Known hypersensitivity to NAD+ or any component of the formulation
- Pregnancy or breastfeeding, where safety data are insufficient
- Uncontrolled cardiovascular conditions without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
NAD+ Nasal Spray, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Compounded NAD+ delivered as a needle-free nasal spray
- Cellular-energy and repair-related biology kept separate from outcome promises
- Schedule set after clinician review
- Prepared by a licensed 503A pharmacy to your individual prescription
- Response and tolerability reviewed through ongoing care
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects the smallest size. Other sizes are shown at checkout.
More in Longevity.
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
Tirzepatide + B12 Microdose
Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care. (Contains tirzepatide and vitamin B12.)
Metformin ER
Diabetes made it famous. Longevity made it interesting again.
FDA-approved generic metformin ER with decades of metabolic use and a serious place in the longevity conversation.
What the research shows
Oral nicotinamide riboside raised the blood NAD+ metabolome, a measurement rather than a health outcome.
The detail
The first clinical pharmacokinetic study of an NAD+ precursor was a randomized, double-blind, three-arm crossover trial in 12 healthy adults aged 30 to 55, in which single oral doses of nicotinamide riboside at 100, 300 and 1,000 mg produced dose-dependent increases in the blood NAD+ metabolome measured over 24 hours. That is a pharmacokinetic measurement, not a health outcome.1
NAD+ rose about 60 percent in blood cells; the endpoint was a biomarker, not health.
The detail
In a two-period, six-week randomized, double-blind, placebo-controlled crossover trial, 30 healthy adults aged 55 to 79 were randomized and 24 completed a regimen of 1,000 mg per day of oral nicotinamide riboside, which raised NAD+ in peripheral blood mononuclear cells by approximately 60 percent relative to placebo. The endpoint met was a change in a blood-cell biomarker, not a change in health.2
Muscle NAD+ rose while muscle mitochondrial function stayed unchanged.
The detail
A randomized, double-blind, placebo-controlled crossover trial gave 1 gram per day of oral nicotinamide riboside to 12 aged men for 21 days and found the skeletal muscle NAD+ metabolome elevated while muscle mitochondrial bioenergetics were unchanged, a direct demonstration that raising NAD+ metabolites in a tissue and improving the function of that tissue are separate results.3
Every metabolic endpoint was unimproved against placebo in men with obesity.
The detail
In a 12-week randomized, double-blind, placebo-controlled parallel-group trial, 40 sedentary men with obesity aged 40 to 70 took 2,000 mg per day of oral nicotinamide riboside, and insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, endogenous glucose production, resting energy expenditure, lipolysis and body composition were all unimproved compared with placebo.4
Insulin-stimulated glucose disposal rose, a small mechanistic finding rather than a clinical benefit.
The detail
A 10-week randomized, double-blind, placebo-controlled trial of 250 mg per day of oral nicotinamide mononucleotide in 25 randomized postmenopausal women with prediabetes who were overweight or obese reported increased insulin-stimulated glucose disposal by hyperinsulinemic-euglycemic clamp and increased skeletal muscle insulin signaling, a single small mechanistic finding rather than an established clinical benefit.5
Oral precursors reliably move NAD metabolites; health outcomes were heterogeneous and often null.
The detail
A systematic review of intervention studies published between January 2010 and October 2025 identified 33 human intervention studies, 28 of them randomized, and concluded that oral nicotinamide riboside and nicotinamide mononucleotide consistently achieved biochemical target engagement in circulating or cellular NAD-related metabolites while effects on functional, metabolic, vascular and other healthspan-relevant outcomes were heterogeneous and often null.6
What it does not show
No published randomized trial of intranasal NAD+ in humans exists for any indication.
The detail
A search of the published literature and the ClinicalTrials.gov registry identified no published randomized controlled trial of intranasal NAD+ in humans for any indication. The intranasal NAD+ literature that exists is preclinical: reduced infarct size in a rat model of transient focal ischemia, reduced hippocampal neuron death in a rat model of traumatic brain injury, and restored olfactory function in mice alongside work in cultured human olfactory stem cells.78910
The one registered intranasal NAD+ study bundles it with other agents and has no results.
The detail
One registered study administering intranasal NAD+ was located, an unmasked randomized pilot with an estimated enrollment of 30 in which a 30 mg per day nasal spray is given together with three or six other agents, a design that cannot isolate any effect attributable to the nasal spray, and for which no results had been posted as of August 2026.11
No approved drug contains NAD+, so no approved dose or indication exists.
The detail
No approved drug product contains NAD+ as an active ingredient. A query of the FDA approved-drug database returned no approved application for nicotinamide adenine dinucleotide by any route, so no approved indication, dose or labeling exists for longevity, cognition, energy or recovery.12
A compounded NAD+ nasal spray is not an FDA-approved drug product.
The detail
A compounded NAD+ nasal spray is not an FDA-approved drug product, and the FDA states that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.13
The precursor trials used different molecules by a different route.
The detail
The precursor trials described above do not transfer to this preparation. Nicotinamide riboside and nicotinamide mononucleotide are different molecules from NAD+, they were given by mouth rather than across the nasal mucosa, and they were given at hundreds to thousands of milligrams per day.12345
No human study has measured whether intranasal NAD+ is absorbed at all.
The detail
No human study has measured whether intranasal NAD+ is absorbed, whether it raises NAD+ in blood or in any tissue, or how long any such change lasts.7
- Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and… Nat Commun. 2016.
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and… Nat Commun. 2018.
- Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+… Cell Rep. 2019.e6.
- Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside… Am J Clin Nutr. 2018.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in… Science. 2021.
- Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided… Ageing Res Rev. 2026.
- Searches of Europe PMC and of the ClinicalTrials.gov registry for intranasal and nasal NAD+ in humans, run 11 August 2026, returning no published randomized controlled trial and no human absorption or pharmacokinetic study.ClinicalTrials.gov
- Ying W, Wei G, Wang D, et al. Intranasal administration with NAD+ profoundly decreases brain injury… Front Biosci. 2007. Animal study.
- Won SJ, Choi BY, Yoo BH, et al. Prevention of traumatic brain injury-induced neuron death by intranasal… J Neurotrauma. 2012. Animal study.
- Yoo SH, Jang JY, Bae JS, et al. Therapeutic effect of intranasal nicotinamide adenine dinucleotide in… Exp Mol Med. 2026. Animal and cell-culture study.
- A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics… ClinicalTrials.gov identifier NCT07475546; randomized, parallel assignment, no masking, estimated enrollment 30, no results posted as of 11 August 2026.ClinicalTrials.gov
- Drugs@FDA, the FDA database of approved drug products, searched for nicotinamide adenine dinucleotide as an active ingredient on 11 August 2026, returning no approved application.FDA
- Compounding and the FDA: Questions and Answers U.S Food and Drug…FDA
Serious risks
- There is no published human safety study of intranasal NAD+, so this route has not been characterized in people
Commonly reported
- From intravenous infusion: nausea, abdominal cramping and chest pressure during administration, which ease once it stops
Because it is a nasal spray
- Stinging
- Dryness
- Irritation of the nasal lining
- A temporary change in smell
The honest starting point is that what is documented for NAD+ comes from intravenous infusion, and with a nasal spray local effects are the ones to watch for. Your provider screens for active sinus infection, recent nasal surgery, nasal polyps, pregnancy and uncontrolled cardiovascular conditions before prescribing, and reviews your medications alongside them. The thinness of the evidence for this route is the reason it sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
The nasal route avoids the needle. Beyond that, the two formulations should not be treated as automatically equivalent. Your provider helps decide which format makes more sense for your goals, history, and willingness to use it consistently.
After clinician approval, the pharmacy prepares the compounded spray for fulfillment. Any time, before your renewal date. No phone calls required.
Nasal irritation, stinging, runny nose, or congestion can occur. Tell your provider about nasal conditions and other medications during your Assessment so tolerability and fit can be considered before prescribing.